Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Context Therapeutics Inc. (NASDAQ:CNTX) has an average rating of "Buy" from analysts, with a target price set at $5.25.
• The company's shares experienced a 6.8% increase, trading at $0.79, while insiders significantly increased their ownership, with the CFO and CEO both purchasing shares.
• Context Therapeutics reported a quarterly earnings loss of ($0.09) EPS, missing expectations of ($0.06) EPS, and analysts forecast a yearly EPS of (-0.51).

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus rating of "Buy" from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.25.

A number of equities analysts have weighed in on CNTX shares. William Blair reiterated an "outperform" rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. Piper Sandler restated an "overweight" rating and issued a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research note on Thursday, June 26th. HC Wainwright lowered their price objective on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, August 7th.

Context Therapeutics Stock Performance

CNTX stock traded up $0.0087 during midday trading on Friday, reaching $0.8810. The stock had a trading volume of 54,142 shares, compared to its average volume of 199,272. The stock has a market cap of $79.03 million, a PE ratio of -2.45 and a beta of 1.89. The firm has a fifty day simple moving average of $0.70 and a two-hundred day simple moving average of $0.75. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.62.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). On average, sell-side analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Insider Activity

In other news, CEO Martin A. Lehr acquired 100,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the acquisition, the chief executive officer owned 920,190 shares in the company, valued at approximately $644,133. This represents a 12.19% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the completion of the acquisition, the chief financial officer owned 80,010 shares in the company, valued at $51,206.40. The trade was a 100.03% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 160,010 shares of company stock worth $107,206. 3.04% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new stake in Context Therapeutics in the fourth quarter valued at approximately $31,000. Millennium Management LLC increased its position in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after acquiring an additional 34,835 shares during the period. Shay Capital LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter worth $52,000. Finally, Geode Capital Management LLC increased its position in shares of Context Therapeutics by 9.2% during the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock worth $661,000 after acquiring an additional 52,830 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.